Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 3-4/2009

01.12.2009

Pathways of metastasis suppression in bladder cancer

verfasst von: Neveen Said, Dan Theodorescu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3-4/2009

Einloggen, um Zugang zu erhalten

Abstract

Despite the recent advances in the diagnosis of bladder cancer, recurrence after surgical intervention for muscle invasive disease is still problematic as nearly half of the patients harbor occult distant metastases and this, in turn, is associated with poor 5-year survival rate. We have recently identified Rho family GDP dissociation inhibitor 2 (RhoGDI2) protein as functional metastasis suppressor and a prognostic marker in patients after cystectomy. In identifying the mechanisms underlying metastasis suppression by RhoGDI2, we found this protein to be associated with the c-Src kinase in human tumors, where the expression of both is diminished as a function of stage. Interestingly, c-Src bound to and phosphorylated RhoGDI2 resulting in enhanced metastasis suppressive potency. In this review, we will discuss the established roles of c-Src and RhoGDI2 in bladder cancer and speculate on their therapeutic relevance.
Literatur
1.
Jemal, A., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4), 225–249.CrossRef
2.
3.
Stein, J. P., et al. (2001). Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. Journal of Clinical Oncology, 19(3), 666–675.PubMed
4.
Theodorescu, D. (2006). Molecular biology of invasive and metastatic urothelial cancer. In S. Lerner, M. Schoenberg, & C. Sternberg (Eds.) Textbook of Bladder Cancer. Taylor and Francis. pp. 147–156.
5.
Gildea, J. J., et al. (2002). RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Research, 62(22), 6418–6423.PubMed
6.
Seraj, M. J., et al. (2000). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clinical & Experimental Metastasis, 18(6), 519–525.CrossRef
7.
Theodorescu, D., et al. (2004). Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clinical Cancer Research, 10(11), 3800–3806.CrossRefPubMed
8.
Titus, B., et al. (2005). Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research, 65(16), 7320–7327.CrossRefPubMed
9.
Wu, Y., et al. (2009). Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5807–5812.CrossRefPubMed
10.
Stehelin, D. (1976). The transforming gene of avian tumor viruses. Pathology and Biology (Paris), 24(8), 513–515.
11.
Stehelin, D., et al. (1976). Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. Journal of Molecular Biology, 101(3), 349–365.CrossRefPubMed
12.
Stehelin, D., et al. (1976). DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 260(5547), 170–173.CrossRefPubMed
13.
Rous, P. (1983). Landmark article (JAMA 1911;56:198). Transmission of a malignant new growth by means of a cell-free filtrate. By Peyton Rous. The Journal of the American Medical Association, 250(11), 1445–1449.
14.
Roskoski, R., Jr. (2004). Src protein-tyrosine kinase structure and regulation. Biochemical and Biophysical Research Communications, 324(4), 1155–1164.CrossRefPubMed
15.
Takeya, T., & Hanafusa, H. (1983). Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. Cell, 32(3), 881–890.CrossRefPubMed
16.
Takeya, T., et al. (1981). Comparison between the viral transforming gene (src) of recovered avian sarcoma virus and its cellular homolog. Molecular and Cellular Biology, 1(11), 1024–1037.PubMed
17.
Iba, H., et al. (1984). Rous sarcoma virus variants that carry the cellular src gene instead of the viral src gene cannot transform chicken embryo fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 81(14), 4424–4428.CrossRefPubMed
18.
Takeya, T., & Hanafusa, H. (1982). DNA sequence of the viral and cellular src gene of chickens. II. Comparison of the src genes of two strains of avian sarcoma virus and of the cellular homolog. Journal of Virology, 44(1), 12–18.PubMed
19.
Moarefi, I., et al. (1997). Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature, 385(6617), 650–653.CrossRefPubMed
20.
Sicheri, F., & Kuriyan, J. (1997). Structures of Src-family tyrosine kinases. Current Opinion in Structural Biology, 7(6), 777–785.CrossRefPubMed
21.
Sicheri, F., Moarefi, I., & Kuriyan, J. (1997). Crystal structure of the Src family tyrosine kinase Hck. Nature, 385(6617), 602–609.CrossRefPubMed
22.
Xu, W., et al. (1999). Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Molecular Cell, 3(5), 629–638.CrossRefPubMed
23.
Manning, G., et al. (2002). The protein kinase complement of the human genome. Science, 298(5600), 1912–1934.CrossRefPubMed
24.
Brown, M. T., & Cooper, J. A. (1996). Regulation, substrates and functions of src. Biochimica et Biophysica Acta, 1287(2–3), 121–149.PubMed
25.
Irby, R. B., & Yeatman, T. J. (2000). Role of Src expression and activation in human cancer. Oncogene, 19(49), 5636–5642.CrossRefPubMed
26.
Levinson, A. D., et al. (1980). The purified product of the transforming gene of avian sarcoma virus phosphorylates tyrosine. Journal of Biological Chemistry, 255(24), 11973–11980.PubMed
27.
Thomas, S. M., & Brugge, J. S. (1997). Cellular functions regulated by Src family kinases. Annual Review of Cell and Developmental Biology, 13, 513–609.CrossRefPubMed
28.
29.
Alland, L., et al. (1994). Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. Journal of Biological Chemistry, 269(24), 16701–16705.PubMed
30.
Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Reviews, 22(4), 337–358.CrossRefPubMed
31.
Summy, J. M., et al. (2005). c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas, 31(3), 263–274.CrossRefPubMed
32.
Irby, R., et al. (1997). Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential. Cell Growth & Differentiation, 8(12), 1287–1295.
33.
Irby, R. B., et al. (1999). Activating SRC mutation in a subset of advanced human colon cancers. Nature Genetics, 21(2), 187–190.CrossRefPubMed
34.
Johnson, F. M., & Gallick, G. E. (2007). SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents in Medical Chemistry, 7(6), 651–659.CrossRef
35.
Mao, W., et al. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene, 15(25), 3083–3090.CrossRefPubMed
36.
Chiang, G. J., et al. (2005). The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt. Journal of the British Association of Urological Surgeons, 96(3), 416–422.
37.
Kopetz, S., et al. (2009). Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Research, 69(9), 3842–3849.CrossRefPubMed
38.
Park, S. I., et al. (2008). Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Research, 68(9), 3323–3333.CrossRefPubMed
39.
Sen, B., et al. (2009). Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Research, 69(5), 1958–1965.CrossRefPubMed
40.
Rosen, N., et al. (1986). Analysis of pp 60c-src protein kinase activity in human tumor cell lines and tissues. Journal of Biological Chemistry, 261(29), 13754–13759.PubMed
41.
Fanning, P., et al. (1992). Elevated expression of pp 60c-src in low grade human bladder carcinoma. Cancer Research, 52(6), 1457–1462.PubMed
42.
Boyer, B., Bourgeois, Y., & Poupon, M. F. (2002). Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene, 21(15), 2347–2356.CrossRefPubMed
43.
Rodier, J. M., et al. (1995). pp 60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. Journal of Cell Biology, 131(3), 761–773.CrossRefPubMed
44.
Thiery, J. P., & Chopin, D. (1999). Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Reviews, 18(1), 31–42.CrossRefPubMed
45.
Simeonova, P. P., et al. (2002). c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis. Journal of Biological Chemistry, 277(4), 2945–2950.CrossRefPubMed
46.
Eblin, K. E., et al. (2007). Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. Toxicological Sciences, 95(2), 321–330.CrossRefPubMed
47.
Yamamoto, N., et al. (2006). Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. Journal of Cell Science, 119(Pt 22), 4623–4633.CrossRefPubMed
48.
DerMardirossian, C., & Bokoch, G. M. (2005). GDIs: central regulatory molecules in Rho GTPase activation. Trends in Cell Biology, 15(7), 356–363.CrossRefPubMed
49.
Golovanov, A. P., et al. (2001). Structure-activity relationships in flexible protein domains: regulation of rho GTPases by RhoGDI and D4 GDI. Journal of Molecular Biology, 305(1), 121–135.CrossRefPubMed
50.
Olofsson, B. (1999). Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal, 11(8), 545–554.CrossRefPubMed
51.
Ota, T., et al. (2006). RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells. Clinical & Experimental Metastasis, 23(7–8), 323–334.
52.
Krieser, R. J., & Eastman, A. (1999). Cleavage and nuclear translocation of the caspase 3 substrate Rho GDP-dissociation inhibitor, D4-GDI, during apoptosis. Cell Death and Differentiation, 6(5), 412–419.CrossRefPubMed
53.
Kwon, K. B., et al. (2002). D4-GDI is cleaved by caspase-3 during daunorubicin-induced apoptosis in HL-60 cells. Experimental and Molecular Medicine, 34(1), 32–37.PubMed
54.
Zhou, X., et al. (2004). Nuclear translocation of cleaved LyGDI dissociated from Rho and Rac during Trp53-dependent ionizing radiation-induced apoptosis of thymus cells in vitro. Radiation Research, 162(3), 287–295.CrossRefPubMed
55.
Ota, T., et al. (2004). LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane. Molecular Carcinogenesis, 39(4), 206–220.CrossRefPubMed
56.
Ma, L., et al. (2007). Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. British Journal of Haematology, 139(2), 217–223.CrossRefPubMed
57.
Tapper, J., et al. (2001). Changes in gene expression during progression of ovarian carcinoma. Cancer Genetics and Cytogenetics, 128(1), 1–6.CrossRefPubMed
58.
Hu, L. D., et al. (2007). Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncology Reports, 17(6), 1383–1389.PubMed
59.
Zhang, B. (2006). Rho GDP dissociation inhibitors as potential targets for anticancer treatment. Drug Resistance Updates, 9(3), 134–141.CrossRefPubMed
60.
Zhang, B., et al. (2005). Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Research, 65(14), 6054–6062.CrossRefPubMed
61.
Zhang, Y., et al. (2009). Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. Journal of Biological Chemistry, 284(19), 12956–12965.CrossRefPubMed
62.
Wang, Y., et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365(9460), 671–679.PubMed
63.
Essmann, F., et al. (2000). GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. Biochemical Journal, 346(Pt 3), 777–783.CrossRefPubMed
64.
DerMardirossian, C., et al. (2006). Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Molecular Biology of the Cell, 17(11), 4760–4768.CrossRefPubMed
65.
Moissoglu, K., et al. (2009). Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases. Cancer Research, 69(7), 2838–2844.CrossRefPubMed
66.
Uhlenbrock, K., et al. (2004). The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. Journal of Cell Science, 117(Pt 20), 4863–4871.CrossRefPubMed
Metadaten
Titel
Pathways of metastasis suppression in bladder cancer
verfasst von
Neveen Said
Dan Theodorescu
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 3-4/2009
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-009-9197-4

Weitere Artikel der Ausgabe 3-4/2009

Cancer and Metastasis Reviews 3-4/2009 Zur Ausgabe

OriginalPaper

Strategies for molecular expression profiling in bladder cancer

OriginalPaper

Biology of urothelial tumorigenesis: insights from genetically engineered mice

OriginalPaper

Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications

OriginalPaper

Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer

NON-THEMATIC REVIEW

MicroRNA function in cancer: oncogene or a tumor suppressor?

OriginalPaper

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise